Last 24 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.21 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.44 | 30.30 | 33.40 | 12.65 | 23.53 | 15.29 | 20.61 | 138.05 | 140.88 | 309.49 | 332.74 | 19.17 | 15.61 | 9.37 | 1.87 | 3.01 | 5.46 | 4.66 | 5.56 | 9.42 | 20.55 |
| — | +98.2% | +62.1% | -90.8% | -83.3% | -95.1% | -93.8% | +620.2% | +802.3% | +3202.0% | +17697.6% | +535.9% | +186.1% | +100.9% | -66.3% | -68.0% | -73.4% | — | — | — | — | |
| P/B Ratio | 0.20 | 1.85 | 1.35 | 1.05 | 1.64 | 1.06 | 0.85 | 1.52 | 2.58 | 2.60 | 6.13 | 3.66 | 1.44 | 0.62 | 0.65 | 0.38 | 0.63 | 0.57 | 0.46 | 0.67 | 1.14 |
| — | +73.4% | +59.0% | -30.8% | -36.4% | -59.1% | -86.1% | -58.4% | +79.6% | +319.9% | +839.5% | +876.4% | +128.3% | +7.7% | +41.5% | -43.9% | -44.7% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | 9.20 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.2% | 100.0% | 29.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 82.2% | 100.0% | 100.0% | 100.0% | 52.1% | 100.0% | -257.3% | -386.3% | -341.8% | -489.0% |
| — | 0.0% | -70.6% | 0.0% | 0.0% | 0.0% | 0.0% | +21.6% | 0.0% | 0.0% | 0.0% | +58.0% | 0.0% | +138.9% | +125.9% | +115.2% | +120.5% | +7.8% | -47.4% | +47.4% | — | |
| Operating Margin | -1315.4% | -2901.3% | -2967.3% | -929.4% | -1475.6% | -1256.6% | -1669.7% | -5520.6% | -3109.8% | -6364.6% | -5542.9% | -296.2% | -636.7% | -781.8% | -334.3% | -602.6% | -493.0% | -375.9% | -535.0% | -497.6% | -656.8% |
| — | -130.9% | -77.7% | +83.2% | +52.6% | +80.3% | +69.9% | -1764.0% | -388.4% | -714.1% | -1558.0% | +50.8% | -29.2% | -108.0% | +37.5% | -21.1% | +24.9% | -0.2% | -37.0% | +49.3% | — | |
| Net Margin | -1256.8% | -2888.6% | -2919.1% | -895.1% | -1422.1% | -1201.3% | -1571.9% | -5384.8% | -2849.1% | -5906.9% | -5325.4% | -272.0% | -591.6% | -763.8% | -331.7% | -604.9% | -483.1% | -372.2% | -534.8% | -497.5% | -656.7% |
| — | -140.5% | -85.7% | +83.4% | +50.1% | +79.7% | +70.5% | -1879.8% | -381.6% | -673.3% | -1505.7% | +55.0% | -22.5% | -105.2% | +38.0% | -21.6% | +26.4% | +0.7% | -37.0% | +49.3% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -71.3% | -36.6% | -26.1% | -17.2% | -22.3% | -19.1% | -15.1% | -15.2% | -12.3% | -16.7% | -22.0% | -12.3% | -12.8% | -17.9% | -25.4% | -17.3% | -13.1% | -10.9% | -10.5% | -8.5% | -11.6% |
| — | -91.6% | -72.2% | -12.9% | -80.4% | -14.1% | +31.3% | -24.2% | +3.5% | +6.5% | +13.4% | +29.2% | +2.2% | -64.4% | -141.2% | -104.3% | -12.9% | -6.5% | +55.3% | — | — | |
| ROA | -43.3% | -16.3% | -13.3% | -9.4% | -12.7% | -11.7% | -9.7% | -10.0% | -8.3% | -10.3% | -11.8% | -7.0% | -7.6% | -9.8% | -12.1% | -10.3% | -10.2% | -9.4% | -9.1% | -7.2% | -9.5% |
| — | -38.9% | -37.2% | +6.0% | -54.0% | -13.8% | +17.5% | -43.1% | -9.4% | -4.9% | +2.9% | +32.2% | +26.0% | -4.1% | -33.5% | -42.1% | -8.1% | -19.5% | -9.3% | +54.0% | — | |
| ROIC | -90.7% | -37.8% | -34.6% | -26.5% | -31.9% | -22.5% | -17.4% | -15.9% | -16.6% | -28.1% | -25.6% | -15.2% | -21.8% | -26.9% | -25.6% | -35.6% | -101.3% | -104.9% | -152.3% | -593.6% | — |
| — | -67.4% | -99.1% | -66.6% | -91.8% | +19.8% | +32.0% | -4.7% | +23.7% | -4.5% | +0.3% | +57.3% | +78.5% | +74.4% | +83.2% | +94.0% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.76 | 1.32 | 0.95 | 0.76 | 0.66 | 0.55 | 0.46 | 0.40 | 0.39 | 0.37 | 0.75 | 0.61 | 0.51 | 0.46 | 1.09 | 0.86 | 0.29 | 0.04 | 0.04 | 0.04 | 0.04 |
| — | +140.7% | +106.8% | +89.2% | +68.3% | +47.5% | -38.1% | -34.0% | -23.4% | -19.4% | -31.8% | -29.1% | +77.2% | +1056.1% | +2721.8% | +2200.7% | +689.0% | -41.7% | -40.6% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.41 | 3.37 | 6.65 | 8.41 | 6.44 | 7.06 | 8.55 | 8.14 | 9.56 | 7.77 | 5.23 | 6.51 | 6.56 | 6.90 | 6.81 | 7.17 | 8.51 | 7.53 | 7.89 | 7.76 | 8.15 |
| — | -52.2% | -22.2% | +3.3% | -32.6% | -9.1% | +63.3% | +25.0% | +45.7% | +12.6% | -23.1% | -9.2% | -22.9% | -8.5% | -13.8% | -7.6% | +4.4% | +41.1% | +20.0% | +271.5% | — | |
| Quick Ratio | 8.41 | 3.37 | 6.65 | 8.41 | 6.44 | 7.06 | 8.55 | 8.14 | 9.56 | 7.77 | 5.23 | 6.51 | 6.56 | 6.90 | 6.81 | 7.17 | 8.51 | 7.53 | 7.89 | 7.76 | 8.15 |
| — | -52.2% | -22.2% | +3.3% | -32.6% | -9.1% | +63.3% | +25.0% | +45.7% | +12.6% | -23.1% | -9.2% | -22.9% | -8.5% | -13.8% | -7.6% | +4.4% | +41.1% | +20.0% | +271.5% | — | |
| Interest Coverage | -45.86 | -42.43 | -40.61 | -31.73 | -50.09 | -52.63 | -49.26 | -44.67 | -30.20 | -32.26 | -30.43 | -22.02 | -22.42 | -23.81 | -22.60 | -18.20 | -79.82 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TCRX stock.
TScan Therapeutics, Inc.'s current P/E is -0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
TScan Therapeutics, Inc.'s current operating margin is -1315.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TScan Therapeutics, Inc.'s business trajectory between earnings reports.